Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

matrixsensorsinc.com

Founded Year

2006

Stage

Unattributed | Alive

Total Raised

$1M

Last Raised

$1M

About Matrix Sensors

Matrix Sensors aims to democratize air quality sensors for a cleaner, healthier, and safer world.

Matrix Sensors Headquarters Location

10655 Roselle Street Suite 200

San Diego, California, 92121,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Matrix Sensors

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Matrix Sensors is included in 1 Expert Collection, including Semiconductors, Chips, and Advanced Electronics.

S

Semiconductors, Chips, and Advanced Electronics

6,135 items

Companies in this collection develop everything from microprocessors to flash memory, integrated circuits specifically for quantum computing and artificial intelligence to OLED for displays, massive production fabs to circuit design firms, and everything in between.

Matrix Sensors Patents

Matrix Sensors has filed 17 patents.

The 3 most popular patent topics include:

  • Metal halides
  • Analytical chemistry
  • Sensors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/30/2018

3/31/2020

Sensors, Gas sensors, Analytical chemistry, Gas technologies, Physical chemistry

Grant

Application Date

8/30/2018

Grant Date

3/31/2020

Title

Related Topics

Sensors, Gas sensors, Analytical chemistry, Gas technologies, Physical chemistry

Status

Grant

Matrix Sensors Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Matrix Sensors Rank

  • When was Matrix Sensors founded?

    Matrix Sensors was founded in 2006.

  • Where is Matrix Sensors's headquarters?

    Matrix Sensors's headquarters is located at 10655 Roselle Street, San Diego.

  • What is Matrix Sensors's latest funding round?

    Matrix Sensors's latest funding round is Unattributed.

  • How much did Matrix Sensors raise?

    Matrix Sensors raised a total of $1M.

  • Who are the investors of Matrix Sensors?

    Investors of Matrix Sensors include UCLA, Miramar Venture Partners and Stanford University.

  • Who are Matrix Sensors's competitors?

    Competitors of Matrix Sensors include Inotek Pharmaceuticals, IntelligentMDx, BioVidria, Helix Therapeutics, Alpha Innotech and 11 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

m
microLAN

microLAN: from chemical analysers to Bioassays:It still is impossible to analyse all chemical substances, which are brought into nature by man. Scientists suggest there are around 100.000 dangerous chemical substances and even with instruments it is still not possible to detect them all. With the help of bioassays a much broader view of the possible dangerous effects can be analysed there where it is most important: nature itself!!With analytical / chemical testing only 5% can be detected, specially in waste and riverwater.Bioassays are more and more commonly used in combination with the traditional chemical analysers for the analyses of soil, water and sediment.

A
Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

Immunetrics Logo
Immunetrics

Nobody prototypes a jet plane or car without running the empirical data through a computer model. A clinical trial is also a prototype. Now, pharmaceutical companies can simulate as many scenarios as necessary to optimize success in the final design of their clinical trials.nBiosimulation technology from Immunetrics Inc. aims to provide a bridge from research and experiment to trial design. Immunetrics' toolset aims to provide predictive computer models based on biological mechanisms. The inputs are patient data; the outputs are predictions of clinical markers over time and clinically relevant endpoints. Using this data, Immunetrics creates a simulation platform for conducting virtual experiments that can help pharmaceutical companies lock down the design of a human study that is optimized for success.nImmunetrics is the only known mechanistic modeling company to provide predictions of clinical trial outcomes that go far beyond pass or fail.

F
Functional Biosciences

Functional Biosciences specializes in genomics research. The company produces reagents and an informatics tools, and aims to provide services that simplify preclinical drug development, reduce the costs of toxicity screening, improve the efficiency of DNA sequencing, and more.

E
EcoAlert

Plymouth Marine Laboratory (PML) has been conducting research into marine organisms for more than 20 years funded by NERC. EcoAlert Ltd has been formed by PML's wholly owned technology transfer company, Plymouth Marine Applications Ltd (PMA), to commercialise a bioassay technique arising from this work. The Company has exclusive rights to ECOBOX, a portable bioassay kits for in-situ analysis of marine, estuarine and freshwater aquatic environments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.